It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Innate immune mediators of pathogen clearance, including the secreted C-type lectins REG3 of the antimicrobial peptide (AMP) family, are known to be involved in the regulation of tissue repair and homeostasis. Their role in metabolic homeostasis remains unknown. Here we show that an increase in human REG3A improves glucose and lipid homeostasis in nutritional and genetic mouse models of obesity and type 2 diabetes. Mice overexpressing REG3A in the liver show improved glucose homeostasis, which is reflected in better insulin sensitivity in normal weight and obese states. Delivery of recombinant REG3A protein to leptin-deficient ob/ob mice or wild-type mice on a high-fat diet also improves glucose homeostasis. This is accompanied by reduced oxidative protein damage, increased AMPK phosphorylation and insulin-stimulated glucose uptake in skeletal muscle tissue. Oxidative damage in differentiated C2C12 myotubes is greatly attenuated by REG3A, as is the increase in gp130-mediated AMPK activation. In contrast, Akt-mediated insulin action, which is impaired by oxidative stress, is not restored by REG3A. These data highlight the importance of REG3A in controlling oxidative protein damage involved in energy and metabolic pathways during obesity and diabetes, and provide additional insight into the dual function of host-immune defense and metabolic regulation for AMP.
Antimicrobial protein REG3A improved insulin sensitivity by combating oxidative stress and activating AMPK in skeletal muscle in HFD-induced obese mice overexpressing human REG3A in the liver.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Paul-Brousse University Hospital, Hepatobiliary Centre, INSERM, U1193, Villejuif, France (GRID:grid.7429.8) (ISNI:0000000121866389); Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
2 Université of Paris, Unité de Biologie Fonctionnelle et Adaptative, Paris, France (GRID:grid.460789.4)
3 Alfact Innovation, Paris, France (GRID:grid.463733.6)
4 University of South Florida, USF Health, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
5 Université of Paris, Unité de Biologie Fonctionnelle et Adaptative, Paris, France (GRID:grid.170693.a)
6 Sorbonne Université, INSERM, NutriOmics team, Institute of Cardiometabolism and Nutrition (ICAN), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France (GRID:grid.170693.a)
7 Paul-Brousse University Hospital, Hepatobiliary Centre, INSERM, U1193, Villejuif, France (GRID:grid.7429.8) (ISNI:0000000121866389); Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535); Medical-University Department (DMU) Biology, Genetics, Pharmacy, Paul-Brousse Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP). Université Paris Saclay, Villejuif, France (GRID:grid.413133.7) (ISNI:0000 0001 0206 8146)